IKBKB
Inhibitor of nuclear factor kappa-B kinase subunit beta
As of the edition of 20 October 2026, IKBKB (inhibitor of nuclear factor kappa-B kinase subunit beta, UniProt O14920) has 2 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O14920
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Hormones; Nutrition and metabolism; Bones, joints and muscles; Cancer; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 37
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bardoxolone methyl | Stopped | Phase 3 | none listed |
| SAR-113945 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Biogen | Route A |
| Kyowa Kirin | Route A |
| Sanofi | Route A |
The other 0 companies at IKBKB
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at IKBKB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.